Pradhana Divya, Priya N Swathi, Manayath George J, Kulkarni Sucheta, Behera Umesh C, Agarwal Tushar, Agarwal Manisha, Shah Shalin, Giridhar A, Surya Janani, Ramasamy Kim, Vignesh T P, Shoba Sivaprasad, Bhende Muna, Raman Rajiv
Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Medical Research Foundation, Chennai, India.
Shri Bhagawan Mahavir Vitreoretinal Services, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Indian J Ophthalmol. 2024 Feb 1;72(2):236-239. doi: 10.4103/IJO.IJO_2182_22. Epub 2023 Dec 26.
We aim to report the natural course of non-center involving diabetic macular edema (NCIDME) progression to center involving diabetic macular edema (CIDME) and associated risk factors.
This is a multicenter retrospective comparative study. Data was collected from electronic medical records from 8 centers in India covering. We included patients with type 2 diabetes above 18 years of age with treatment-naïve NCIDME on OCT and best-corrected visual acuity at baseline of 6/12 or better who were under observation for NCIDME and had 2 years follow-up data.
Out of 72 patients with NCIDME, 26.38% patients progressed to CI DME by 2 years, and the visit wise proportion was 11.11% at 6 months, 7% at 1st year and 8.3% at 2 years. The change in CST was statistically significant at 2 years in patients who developed CIDME, the mean difference was 137.73 ± 48.56 microns p = 0.045. Duration of diabetes mellitus > 10 years was the only risk factor for conversion to CIDME.
A quarter of eyes with NCIDME developed CIDME and 15% progressed from NPDR to PDR by 2 years, highlighting the disease burden in these patients with NCIDME.
我们旨在报告非累及黄斑中心凹的糖尿病性黄斑水肿(NCIDME)进展为累及黄斑中心凹的糖尿病性黄斑水肿(CIDME)的自然病程及相关危险因素。
这是一项多中心回顾性对照研究。数据从印度8个中心的电子病历中收集。我们纳入了年龄在18岁以上的2型糖尿病患者,这些患者在OCT检查中初诊为NCIDME,基线最佳矫正视力为6/12或更好,正在接受NCIDME观察且有2年随访数据。
在72例NCIDME患者中,26.38%的患者在2年内进展为CIDME,按就诊时间划分的比例分别为:6个月时为11.11%,1年时为7%,2年时为8.3%。发生CIDME的患者在2年时CST的变化具有统计学意义,平均差值为137.73±48.56微米,p = 0.045。糖尿病病程>10年是转化为CIDME的唯一危险因素。
四分之一的NCIDME患眼发展为CIDME,15%的患者在2年内从非增殖性糖尿病视网膜病变(NPDR)进展为增殖性糖尿病视网膜病变(PDR),突出了这些NCIDME患者的疾病负担。